Multimodal therapy in malignant pleural mesothelioma (MPM) Source: Eur Respir J 2002; 20: Suppl. 38, 187s Year: 2002
Second-line chemotherapy in malignant pleural mesothelioma (MPM) Source: Eur Respir J 2002; 20: Suppl. 38, 273s Year: 2002
Systemic therapy 1 in malignant pleural mesothelioma: chemotherapy Source: ERS Online Course 2020: Calendar sheets in malignant pleural diseases Year: 2020
Evaluation of intrapericardial cisplatin (CIS) administration in cases with recurrent malignant pericardial effusion (MPE) in pts with lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 63s Year: 2003
Malignant pleural mesothelioma (MPM) – 5 years of experience Source: Eur Respir J 2006; 28: Suppl. 50, 91s Year: 2006
Tumour marker (TM) CA 19-9 in pleural fluid at patients with malignant and paramalignant pleural effusion (PE) Source: Eur Respir J 2001; 18: Suppl. 33, 387s Year: 2001
Treatment successes with talc pleurodesis at patients (pts.) with recurrent malignant pleural effusions (PE) Source: Eur Respir J 2002; 20: Suppl. 38, 438s Year: 2002
Efficacy of pleurodesis for malignant pleural effusions in breast cancer patients Source: Eur Respir J 2011; 38: 1425-1430 Year: 2011
Systemic treatment of malignant mesothelioma Source: Eur Respir Mon; 2009: 44: 419–434 Year: 2009
Systemic therapy 2 in malignant pleural mesothelioma: immuno- & targeted therapy Source: ERS Online Course 2020: Calendar sheets in malignant pleural diseases Year: 2020
Treatment of malignant pleural mesothelioma with caelyx: few responses but good survival Source: Eur Respir J 2004; 24: Suppl. 48, 526s Year: 2004
Tumor markers (TM) CEA, MCA and CA 19-9 in pleural effusion (PE) at malignant mezothelioma and methastatic tumour of pleura Source: Eur Respir J 2003; 22: Suppl. 45, 61s Year: 2003
Systemic treatment of malignant pleural effusion Source: Annual Congress 2005 - What's new in the pleura Year: 2005
Metastatic pleural effusions (mpes) Source: Annual Congress 2008 - Various aspects of thoracic oncology Year: 2008
Prognostic factors associated to survival in patients with malignant pleural effusion (MPE) undergoing talc poudrage pleurodesis (TPP) Source: International Congress 2016 – Malignant pleural disease: diagnosis and management Year: 2016
Malignant pleural mesothelioma: new treatment modalities Source: Annual Congress 2005 - Clinical year in review Year: 2005
Comparison between mesothelin and fibulin-3 detection in pleural malignant mesothelioma (MPM) patients Source: International Congress 2016 – Mesothelioma and malignant pleural disease Year: 2016
Malignant pleural mesothelioma (MPM): clinical presentation, complications and survival Source: Eur Respir J 2002; 20: Suppl. 38, 272s Year: 2002
Role of surgery and of radiotherapy in malignant pleural mesothelioma Source: ERS Online Course 2020: Calendar sheets in malignant pleural diseases Year: 2020
An examination of the factors for successful pleurodesis against malignant pleural effusion (MPE) Source: International Congress 2016 – Mesothelioma and malignant pleural disease Year: 2016